A groundbreaking study on the obesity treatment Wegovy has uncovered that patients can maintain a significant reduction in weight for a minimum of four years, experiencing fewer severe side effects in comparison to those on placebo treatments.
Such evidence is likely to influence healthcare policymakers in the UK, where current regulations restrict the duration of this medication to two years.
Unveiled at a major obesity symposium, the research indicated that participants receiving weekly Wegovy injections continued to lose weight for the initial 65 weeks and subsequently maintained a consistent body weight over an extended period.
Recorded results demonstrate an average weight reduction of 10.2% and a waistline decrease of 7.7cm at the four-year mark.
Remarkably, this was consistent among those who were slightly obese or those who experienced modest weight loss, with measurable benefits that included lowered cardiovascular risks. These findings were presented at the European Congress on Obesity in Venice and simultaneously published in Nature Medicine.
Dr. Simon Cork, a physiology expert from Anglia Ruskin University not directly involved in the study, emphasized that these outcomes affirm that ongoing treatment helps patients retain a “weight plateau.” He commented on the current limitations imposed by UK health services regarding the treatment duration, suggesting that the four-year data could challenge the existing views on long-term cost effectiveness.
The SELECT (Semaglutide and Cardiovascular Outcomes) trial involved 17,604 adults across 41 countries. These individuals were either obese or overweight, with a history of heart attack, stroke, or peripheral artery disease, but without diabetes.
The trial highlighted that obesity rates within the Wegovy-treated group plummeted from 71% to 43% over two years, whereas the placebo group saw only a marginal decline from 72% to 68%.
Risks of heart attack, stroke, or death due to cardiovascular issues were shown to decrease by 20% after three years of Wegovy treatment according to previous year’s published data.
Professor Donna Ryan, who spearheaded this study, confirmed that the weight loss exhibited was comprehensive, covering various demographics inclusive of age, gender, and ethnicity.
Despite a focus on cardiovascular events during the study, Ryan proposed that a plethora of chronic conditions, such as certain cancers, osteoarthritis, and mental health disorders, would benefit from effective weight management solutions.
The study also highlighted that participants on Wegovy encountered serious adverse incidents less frequently than the placebo group. The difference was mainly attributed to a reduced occurrence of cardiac disorders among Wegovy users.
While gallbladder stones and gastrointestinal issues like nausea and diarrhea were more common with Wegovy, resulting in some discontinuations, the overall safety profile remained favorable.
Further research by UK scientists affirmed cardiovascular advantages even in those with mild obesity or minimal weight loss. Findings suggest that Wegovy may exert benefits through mechanisms other than fat reduction, potentially affecting blood sugar, blood pressure, inflammation, and direct heart and vessel health.
However, the team cautioned that evidence is still needed to confirm if long-term Wegovy treatment prevents major cardiovascular events.
Semaglutide, Wegovy’s primary component, is part of a class of drugs known as GLP-1 medications which enhance satiety and reduce calorie intake.
FAQs About Wegovy Obesity Drug
What is Wegovy and how does it work?
Wegovy is an obesity treatment containing semaglutide. It functions as a GLP-1 agonist, increasing feelings of fullness and thus leading to reduced calorie consumption.
How long can patients expect to use Wegovy?
Based on the study, patients can maintain weight loss for at least four years. However, UK health services currently restrict use to two years. This may change with new evidence.
Are there any side effects associated with Wegovy?
Some patients may experience gastrointestinal symptoms, such as nausea and diarrhea, or develop gallbladder stones. Serious adverse events are less common compared to placebo.
Can Wegovy benefit patients with mild obesity or those who lose minimal weight?
Yes, cardiovascular benefits were noted even in participants with mild obesity or modest weight loss.
Conclusion
Wegovy has demonstrated the capacity to support patients in attaining and upholding substantial weight loss for a period extending up to four years. Notably, the drug’s safety profile is reassuring, showing fewer serious complications than placebo treatments. With the emergence of this compelling evidence, a re-evaluation of the drug’s treatment duration in healthcare policies may be imminent, potentially affecting the management strategies for obesity-related health conditions and their associated risks on a global scale.
